CA00288U1066
© BusinessWire
08.12.2025
ABCL
LISTED
NASDAQ
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the prese...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ABCL
LISTED
NASDAQ
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
News Preview
AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director.
Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genom...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ABCL
LISTED
NASDAQ
AbCellera Reports Q3 2025 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substant...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
07.10.2025
ABCL
LISTED
NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
Truist Securities BioPharma Symposium, November 6, 2025
Stifel Healthcare Conference, November 11-13, 2025
Jefferies Global Healthcare Conference, November 18-20, 2025
Piper Sandler 37th Annual Healthcare Conference, Decemb...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
29.09.2025
ABCL
LISTED
NASDAQ
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations w...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
ABCL
LISTED
NASDAQ
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
News Preview
AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of ind...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ABCL
LISTED
NASDAQ
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
News Preview
AbCellera (Nasdaq: ABCL) today announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 targets OX40...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
ABCL
LISTED
NASDAQ
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations we...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
ABCL
LISTED
NASDAQ
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
News Preview
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential application...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
ABCL
LISTED
NASDAQ
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
News Preview
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), co...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
ABCL
LISTED
NASDAQ
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
News Preview
AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 (“the ‘408 Patent”). AbCellera’s ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.
Pre...
Themefolio
Profiler
Peergroup
© BusinessWire
10.05.2025
ABCL
LISTED
NASDAQ
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
News Preview
AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California.
AbCellera’s presentation, which is available for viewing here, describes key properties of ABCL575, including:
Potent functio...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.05.2025
ABCL
LISTED
NASDAQ
AbCellera Reports Q1 2025 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
ABCL
LISTED
NASDAQ
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30, 2025.
Targeting prostate-specific membrane antigen (PSMA) with a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
ABCL
LISTED
NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in May and June
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
Bloom Burton & Co. Healthcare Investor Conference, May 5-6
Goldman Sachs 46th Annual Global Healthcare conference, June 9-11
Visit AbCellera's Investor Relations website for additional information.
About AbCellera Biologics...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
ABCL
LISTED
NASDAQ
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
ABCL
LISTED
NASDAQ
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
News Preview
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois.
Details on AbCellera’s poster prese...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ABCL
LISTED
NASDAQ
AbCellera Reports Full Year 2024 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and compl...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
ABCL
LISTED
NASDAQ
AbCellera to Participate at Upcoming Investor Conferences in March
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
45th Annual TD Cowen Health Care Conference, March 3-5
KeyBanc Capital Markets Healthcare Forum, March 18-19
Visit AbCellera's Investor Relations website for additional information.
About AbCellera Biologics Inc.
AbCellera...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
ABCL
LISTED
NASDAQ
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
News Preview
AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations webs...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ABCL
LISTED
NASDAQ
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
News Preview
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ABCL
LISTED
NASDAQ
AbCellera to Present at Upcoming Investor Conferences in December and January
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:
Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time)
43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on W...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
ABCL
LISTED
NASDAQ
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas.
AbCellera’s presentation, which is available for viewing here, describes:
Strategies to address key c...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ABCL
LISTED
NASDAQ
AbCellera Reports Q3 2024 Business Results
News Preview
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
ABCL
LISTED
NASDAQ
AbCellera to Present at Upcoming Investor Conferences in November 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
ABCL
LISTED
NASDAQ
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
News Preview
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas.
Details on AbCellera’s poster presentation at SITC are as follows:
Title: Profiling bispecific T-cell engagers: Strategies...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ABCL
LISTED
NASDAQ
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
News Preview
AbCellera (Nasdaq: ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations webs...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
ABCL
LISTED
NASDAQ
AbCellera to Present at Upcoming Investor Conferences in September
News Preview
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time)
Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:30 a.m. Pacific Time...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
